Multi-peptide vaccination with fusion peptide spanning the BCR–ABL fusion showed a specific immune response and improved disease control in patients with chronic myeloid leukemia [39,40]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.